{"id":"chidamide-fulvestrant","safety":{"commonSideEffects":[{"rate":null,"effect":"Thrombocytopenia"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Hot flashes"}]},"_chembl":{"chemblId":"CHEMBL4087968","moleculeType":"Small molecule","molecularWeight":"390.42"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Chidamide is a histone deacetylase (HDAC) inhibitor that promotes acetylation of histones, leading to chromatin remodeling and reactivation of silenced tumor suppressor genes. Fulvestrant is a selective estrogen receptor degrader (SERD) that binds to and degrades the estrogen receptor, eliminating estrogen-dependent signaling. The combination targets both epigenetic regulation and hormone-driven proliferation in estrogen receptor-positive breast cancer.","oneSentence":"Chidamide inhibits histone deacetylases to reactivate tumor suppressor genes, while fulvestrant blocks estrogen receptor signaling to inhibit hormone-dependent breast cancer growth.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:29:55.042Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Estrogen receptor-positive, HER2-negative breast cancer"}]},"trialDetails":[{"nctId":"NCT06750848","phase":"PHASE2","title":"Chidamide Combined With Angiogenesis Inhibitors and Fulvestrant for Advanced HR-positive, HER2-negative Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"Jundong Wu","startDate":"2024-12-20","conditions":"Advanced Breast Cancer","enrollment":48},{"nctId":"NCT05983107","phase":"PHASE2","title":"Chidamide/Everolimus for PIK3CA Wild-type/Mutant HR+/HER2- Advanced Breast Cancer","status":"RECRUITING","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2023-07-20","conditions":"HR+/HER2- Advanced Breast Cancer, Targeted Therapy","enrollment":102},{"nctId":"NCT05890287","phase":"NA","title":"A Study of Chidamide Plus Endocrine in Maintenance Treatment of HR+/HER2- Breast Cancer After First-line Chemotherapy","status":"RECRUITING","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2023-05-16","conditions":"HR Positive HER2 Negative Advanced Breast Cancer","enrollment":60},{"nctId":"NCT05808582","phase":"PHASE2","title":"Chidamide Combined With Fulvestrant for HR+/HER2-advanced Breast Cancer","status":"UNKNOWN","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2023-05-01","conditions":"Hormone Receptor-positive Advanced Breast Cancer","enrollment":60},{"nctId":"NCT05806047","phase":"PHASE2","title":"Combination of Chidamide and Fulvestrant for HR+/HER2- Breast Cancer That Has Failed Previous CDK4/6 i Adjuvant Therapy","status":"UNKNOWN","sponsor":"Fudan University","startDate":"2023-05-01","conditions":"Hormone Receptor-positive Advanced Breast Cancer","enrollment":23},{"nctId":"NCT05411380","phase":"PHASE2","title":"Tucidinostat Combined With Metronomic Capecitabine and Endocrine Therapy for Advanced HR-positive, HER2-negative Breast Cancer After CDK4/6 Inhibitor.","status":"UNKNOWN","sponsor":"wang shusen","startDate":"2022-10-03","conditions":"Breast Cancer","enrollment":73},{"nctId":"NCT05186545","phase":"PHASE2","title":"An Exploratory Study of Surufatinib Combined With Chidamide and Fulvestrant in HR Positive Unresectable Metastatic Breast Cancer","status":"UNKNOWN","sponsor":"The First Affiliated Hospital of Zhengzhou University","startDate":"2022-07-01","conditions":"Breast Cancer, Breast Cancer Female","enrollment":63},{"nctId":"NCT05191914","phase":"PHASE4","title":"Clinical Study of Fulvestrant Combined With Chidamide in the Treatment of Hormone Receptor-positive Advanced Breast Cancer Resistant to CDK4/6 Inhibitors","status":"UNKNOWN","sponsor":"Liaoning Cancer Hospital & Institute","startDate":"2022-02-07","conditions":"Breast Cancer","enrollment":20},{"nctId":"NCT05047848","phase":"NA","title":"Clinical Study of Chidamide Combined With Fulvestrant in the Treatment of Hormone Receptor-positive Advanced Breast Cancer","status":"UNKNOWN","sponsor":"Liaoning Cancer Hospital & Institute","startDate":"2021-08-18","conditions":"Advanced Breast Cancer","enrollment":82},{"nctId":"NCT04999540","phase":"PHASE2","title":"Tucidinostat and Fulvestrant in Hormone-receptor Positive Advanced Breast Cancer","status":"UNKNOWN","sponsor":"Guangdong Women and Children Hospital","startDate":"2021-11-01","conditions":"Breast Cancer","enrollment":73}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Chidamide+ Fulvestrant","genericName":"Chidamide+ Fulvestrant","companyName":"Liaoning Cancer Hospital & Institute","companyId":"liaoning-cancer-hospital-institute","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Chidamide is a small molecule used in targeted therapy for breast cancer. It is being studied in combination with Fulvestrant for the treatment of hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}